- Home
- UHS vs EXAS Comparison
UHS vs EXAS Comparison
Compare UHS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- EXAS
- Stock Information
- Founded
- UHS 1978
- EXAS 1995
- Country
- UHS United States
- EXAS United States
- Employees
- UHS N/A
- EXAS N/A
- Industry
- UHS Hospital/Nursing Management
- EXAS Medical Specialities
- Sector
- UHS Health Care
- EXAS Health Care
- Exchange
- UHS Nasdaq
- EXAS Nasdaq
- Market Cap
- UHS 13.4B
- EXAS 11.0B
- IPO Year
- UHS N/A
- EXAS N/A
- Fundamental
- Price
- UHS $230.14
- EXAS $68.66
- Analyst Decision
- UHS Buy
- EXAS Strong Buy
- Analyst Count
- UHS 13
- EXAS 18
- Target Price
- UHS $231.62
- EXAS $72.44
- AVG Volume (30 Days)
- UHS 637.3K
- EXAS 2.9M
- Earning Date
- UHS 10-27-2025
- EXAS 11-03-2025
- Dividend Yield
- UHS 0.36%
- EXAS N/A
- EPS Growth
- UHS 39.76
- EXAS N/A
- EPS
- UHS 21.01
- EXAS N/A
- Revenue
- UHS $16,992,503,000.00
- EXAS $3,082,033,000.00
- Revenue This Year
- UHS $10.41
- EXAS $16.68
- Revenue Next Year
- UHS $4.93
- EXAS $12.36
- P/E Ratio
- UHS $10.68
- EXAS N/A
- Revenue Growth
- UHS 10.21
- EXAS 14.47
- 52 Week Low
- UHS $152.33
- EXAS $38.81
- 52 Week High
- UHS $229.76
- EXAS $72.81
- Technical
- Relative Strength Index (RSI)
- UHS 68.02
- EXAS 69.70
- Support Level
- UHS $217.26
- EXAS $66.14
- Resistance Level
- UHS $229.76
- EXAS $72.81
- Average True Range (ATR)
- UHS 7.26
- EXAS 2.16
- MACD
- UHS 0.32
- EXAS -0.09
- Stochastic Oscillator
- UHS 97.81
- EXAS 61.04
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.